Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow LivaNova PLC

Get SEC filing alerts via email and in your feed for LivaNova PLC

LIVN

LivaNova PLC

About LivaNova PLC

LivaNova PLC is a global medical technology company specializing in devices for neurological and cardiac conditions. Its core segments include Cardiopulmonary products like heart-lung machines and oxygenators, and Neuromodulation therapies such as vagus nerve stimulation for epilepsy and depression. The company develops innovative, regulatory-compliant solutions for hospitals worldwide, emphasizing quality, clinical evidence, and cost-effective delivery to improve patient outcomes.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from LivaNova PLC

1
1
LivaNova PLC LivaNova Reports 14.3% Revenue Growth to $362.3 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
LivaNova PLC LivaNova Reports 10.7% Revenue Growth to $1.39 Billion Despite Net Loss

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
LivaNova PLC LivaNova Reports $357.8 Million Revenue in Q3 2025, Net Loss of $273.4 Million for Nine Months

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
LivaNova PLC LivaNova Reports 10.7% Revenue Growth to $352.5 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
LivaNova PLC LivaNova Reports $316.9 Million Revenue in Q1 2025, Faces $327.3 Million Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
LivaNova PLC LivaNova Reports $1.25 Billion Revenue for Fiscal Year 2024, Up 8.7%

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
LivaNova PLC LivaNova Reports Strong Financial Improvements in Q3 and Nine Months of 2024

Via official filing (AI summary) | over 1 year ago | 0 comments